COMMUNIQUÉS West-GlobeNewswire

genedrive to premier its Genedrive® Hepatitis C test in Asia Pacific

03/04/2018 - 08:00

3 April 2018 genedrive plc ("genedrive" or the "Company") Genedrive® HCV ID Kit to be presented at MEDLAB Asia Pacific Exhibition & Congress genedrive plc (AIM: GDR), the near patient molecular diagnostics company, [...]

Motif Bio Initiates NDA Rolling Submission for Iclaprim and Provides Business Update

03/04/2018 - 08:00

NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ: MTFB ), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the initiation of a rolling [...]

DBV Technologies to Attend the 11th Kempen Life Sciences Conference

03/04/2018 - 07:31

Montrouge, April 3, 2018 DBV Technologies to Attend the 11 th Kempen Life Sciences Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Chief [...]

DBV Technologies invitée à participer à la 11ème Life Sciences Conference de Kempen

03/04/2018 - 07:31

Montrouge, France, le 3 avril, 2018 (7H30 CEST) DBV Technologies invitée à participer à la 11ème Life Sciences Conference de Kempen DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq : DBVT), une société [...]

Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma

03/04/2018 - 07:01

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma Paris and Tarrytown, NY - April 3, 2018 - The European Medicines [...]

Sanofi : L'EMA va examiner le cemiplimab comme traitement potentiel du carcinome épidermoïde cutané au stade avancé

03/04/2018 - 07:01

Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) L'EMA va examiner le cemiplimab comme traitement potentiel du carcinome épidermoïde cutané au stade avancé Paris et Tarrytown (New York) - Le 3 avril [...]

Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma

03/04/2018 - 07:01

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) EMA to review Dupixent ® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma Paris and Tarrytown, NY - April 3, 2018 - The [...]

Sanofi : L'EMA va examiner Dupixent® (dupilumab) dans le traitement potentiel de l'asthme modéré à sévère inadéquatement contrôlé

03/04/2018 - 07:01

Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) L'EMA va examiner Dupixent® (dupilumab) dans le traitement potentiel de l'asthme modéré à sévère inadéquatement contrôlé Paris et Tarrytown (New York [...]

Fagron strengthens strategic position in USA through highly complementary acquisition of Humco

03/04/2018 - 07:01

Nazareth (Belgium)/Rotterdam (The Netherlands) 1 , 3 April 2018 Regulated information - Inside information Fagron strengthens strategic position in USA through highly complementary acquisition of Humco Fagron announces [...]

argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting

03/04/2018 - 07:01

Company to host workshop and webcast on April 24, 2018 at 1:00 p.m. PT April 3, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a [...]

Probiodrug reports full year 2017 financial results

03/04/2018 - 07:01

Probiodrug reports full year 2017 financial results PQ912 delivers positive pharmacodynamic and efficacy results in a Phase 2a study in early stage AD patients - data presented at CTAD, Boston, November 2017 PQ912 Phase [...]

Veloxis Appoints Morten Marott as Chief Financial Officer

03/04/2018 - 05:13

Company Release no. 08/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 03 April 2018 Veloxis Appoints Morten Marott as Chief Financial Officer Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that Morten [...]

Operational Update

03/04/2018 - 02:38

First two patients of the additional cohort of the Phase I, TACTI-mel trial have commenced treatment; data to be reported mid-2018 AIPAC trial: 33 out of a planned 34 clinical sites now active with full recruitment [...]

REVA Initiates Commercial Distribution Partnership in Turkey

03/04/2018 - 01:30

SAN DIEGO, April 02, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced that it will initiate commercial [...]

TLC Announces Application with U.S. FDA for Proceeding of TLC590 as Investigational New Drug (IND)

03/04/2018 - 00:59

TAIPEI, Taiwan, April 03, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (“TLC”), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel [...]

Pacific Health Care Organization, Inc. Reports its 2017 Year-End Financial Results

02/04/2018 - 23:07

Newport Beach, CA , April 02, 2018 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) today filed with the Securities and Exchange Commission (the “Commission”) its annual report [...]

Microbix Announces Annual and Special Meeting Voting Results

02/04/2018 - 23:00

TORONTO, April 02, 2018 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX ) (Microbix®), an innovator of biological products and technologies, announces the voting results from the Annual and Special Meeting of [...]

Assembly Biosciences Appoints Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer Microbiome

02/04/2018 - 22:54

INDIANAPOLIS and SAN FRANCISCO, April 02, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB ), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of [...]

MacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

02/04/2018 - 22:30

ROCKVILLE, MD, April 02, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]